
PMC - PMC2670986
PMID- 19350330
IS  - 0884-8734 (Print)
IS  - 1525-1497 (Electronic)
VI  - 24
IP  - Suppl 1
DP  - 2009 Apr
TI  - Scientific Abstracts.
PG  - 1-380
LA  - eng
PT  - Journal Article
DEP - 20090407
TA  - J Gen Intern Med
JT  - Journal of General Internal Medicine
AID - 963 [pii]
AID - 10.1007/s11606-009-0963-3 [doi]
SO  - J Gen Intern Med. 2009 Apr;24(Suppl 1):1-380. Epub 2009 Apr 7
      doi:10.1007/s11606-009-0963-3.

PMC - PMC5011511
PMID- 27642529
IS  - 2090-6528 (Print)
IS  - 2090-6536 (Electronic)
VI  - 2016
DP  - 2016
TI  - An Unusual Cause of Acute Upper Gastrointestinal Bleeding: Acute Esophageal
      Necrosis.
LID - 6584363
AB  - Acute esophageal necrosis (AEN), also called “black esophagus,” is a condition
      characterized by circumferential necrosis of the esophagus with universal distal 
      involvement and variable proximal extension with clear demarcation at the
      gastroesophageal junction. It is an unusual cause of upper gastrointestinal
      bleeding and is recognized with distinct and striking mucosal findings on
      endoscopy. The patients are usually older and are critically ill with shared
      comorbidities, which include atherosclerotic cardiovascular disease, diabetes
      mellitus, hypertension, chronic renal insufficiency, and malnutrition. Alcoholism
      and substance abuse could be seen in younger patients. Patients usually have
      systemic hypotension along with upper abdominal pain in the background of
      clinical presentation of hematemesis and melena. The endoscopic findings confirm 
      the diagnosis and biopsy is not always necessary unless clinically indicated in
      atypical presentations. Herein we present two cases with distinct clinical
      presentation and discuss the endoscopic findings along with a review of the
      published literature on the management of AEN.
FAU - Kalva, Nikhil R.
AU  - Kalva NR
AUID- ORCID: 0000-0003-0444-367X
AD  - Division of Gastroenterology and Hepatology, University of Illinois College of
      Medicine at Peoria, IL, USA
FAU - Tokala, Madhusudhan R.
AU  - Tokala MR
AD  - Department of Pharmacology and Pathophysiology, St. George's University School of
      Medicine, St. George's, West Indies, Grenada
FAU - Dhillon, Sonu
AU  - Dhillon S
AD  - Division of Gastroenterology and Hepatology, University of Illinois College of
      Medicine at Peoria, IL, USA
FAU - Pisoh, Watcoun-Nchinda
AU  - Pisoh WN
AD  - Division of Gastroenterology and Hepatology, University of Illinois College of
      Medicine at Peoria, IL, USA
FAU - Walayat, Saqib
AU  - Walayat S
AD  - Division of Gastroenterology and Hepatology, University of Illinois College of
      Medicine at Peoria, IL, USA
FAU - Vanar, Vishwas
AU  - Vanar V
AD  - Division of Gastroenterology and Hepatology, University of Illinois College of
      Medicine at Peoria, IL, USA
FAU - Puli, Srinivas R.
AU  - Puli SR
AD  - Division of Gastroenterology and Hepatology, University of Illinois College of
      Medicine at Peoria, IL, USA
LA  - eng
PT  - Journal Article
DEP - 20160823
PHST- 2016/02/06 [received]
PHST- 2016/06/13 [revised]
PHST- 2016/06/27 [accepted]
PHST- 2016/08/23 [aheadofprint]
TA  - Case Rep Gastrointest Med
JT  - Case Reports in Gastrointestinal Medicine
AID - 10.1155/2016/6584363 [doi]
SO  - Case Rep Gastrointest Med. 2016;2016:. Epub 2016 Aug 23 doi:10.1155/2016/6584363.

PMC - PMC2423597
IS  - 0894-8569 (Print)
IS  - 1607-8462 (Electronic)
VI  - 2
IP  - Suppl
DP  - 1990
TI  - Free Papers.
PG  - 1-267
LA  - eng
PT  - Journal Article
TA  - HPB Surg
JT  - HPB Surgery
AID - S0894856990724046 [pii]
AID - 10.1155/1990/72404 [doi]
SO  - HPB Surg. 1990;2(Suppl):1-267. doi:10.1155/1990/72404.

PMC - PMC4389133
PMID- 25859384
IS  - 2048-8505 (Print)
IS  - 2048-8513 (Electronic)
VI  - 7
IP  - 6
DP  - 2014 Dec
TI  - Black esophagus in the early kidney post-transplant period.
PG  - 613-4
FAU - Caravaca-Fontán, Fernando
AU  - Caravaca-Fontán F
FAU - Jimenez, Sara
AU  - Jimenez S
FAU - Fernández-Rodríguez, Ana
AU  - Fernández-Rodríguez A
FAU - Marcén, Roberto
AU  - Marcén R
FAU - Quereda, Carlos
AU  - Quereda C
LA  - eng
PT  - Journal Article
DEP - 20140914
PHST- 2014/06/01 [received]
PHST- 2014/08/15 [accepted]
PHST- 2014/09/14 [aheadofprint]
TA  - Clin Kidney J
JT  - Clinical Kidney Journal
AID - 10.1093/ckj/sfu094 [doi]
AID - sfu094 [pii]
SO  - Clin Kidney J. 2014 Dec;7(6):613-4. Epub 2014 Sep 14 doi:10.1093/ckj/sfu094.

PMC - PMC4449347
PMID- 25503648
IS  - 1875-2292 (Print)
IS  - 1875-2284 (Electronic)
VI  - 8
IP  - 1
DP  - 2015 Apr
TI  - Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A 
      Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and
      Low-Dose Treosulfan.
PG  - 33-41
AB  - Therapeutic options for patients with castration-resistant prostate cancer (CRPC)
      remain limited. In a multicenter, Phase II study, 65 patients with histologically
      confirmed CRPC received a biomodulatory regimen during the six-month core study. 
      Treatment comprised daily doses of imatinib mesylate, pioglitazone, etoricoxib,
      treosulfan and dexamethasone. The primary endpoint was prostate-specific antigen 
      (PSA) response. Responders could enter an extension phase until disease
      progression or intolerable toxicity occurred. Mean PSA was 45.3 ng/mL at
      baseline, and 77 % of patients had a PSA doubling time <3 months. Of the 61
      evaluable patients, 37 patients (60.6 %) responded or had stable disease and 23
      of them (37.7 % of 61 patients) were PSA responders. Among the 23 responders mean
      PSA decreased from 278.9 ± 784.1 ng/mL at baseline to 8.8 ± 11.6 ng/mL at the
      final visit (week 24). The progression-free survival (PFS) was 467 days in the
      ITT population. Of the 947 adverse events, 57.6 % were suspected to be
      drug-related, 13.8 % led to dose adjustment or permanent discontinuation and
      40.2 % required concomitant medication. This novel combination approach led to an
      impressive PSA response rate of 37.7 % in CRPC patients. The good PSA response
      and PFS rate combined with the manageable toxicity profile suggest an alternative
      treatment option.
FAU - Vogelhuber, M.
AU  - Vogelhuber M
AD  - Department of Hematology and Oncology, University Hospital Regensburg,
      Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany
FAU - Feyerabend, S.
AU  - Feyerabend S
AD  - Department of Urology, University Hospital Tuebingen, Hoppe-Seyler-Strasse 3,
      72076 Tuebingen, Germany
FAU - Stenzl, A.
AU  - Stenzl A
AD  - Department of Urology, University Hospital Tuebingen, Hoppe-Seyler-Strasse 3,
      72076 Tuebingen, Germany
FAU - Suedhoff, T.
AU  - Suedhoff T
AD  - Department of Hematology and Oncology, Hospital Passau, Innstrasse 76, 94032
      Passau, Germany
FAU - Schulze, M.
AU  - Schulze M
AD  - Outpatient Center for Urology and Oncology, Hauptstrasse 10, 04416 Markkleeberg, 
      Germany
FAU - Huebner, J.
AU  - Huebner J
AD  - Department of Oncology, J. W. Goethe University, Theodor-Stern-Kai 7, 60323
      Frankfurt, Germany
FAU - Oberneder, R.
AU  - Oberneder R
AD  - Urologic Hospital München-Planegg, Germeringer Str. 32, 82152 Planegg, Germany
FAU - Wieland, W.
AU  - Wieland W
AD  - Department of Urology, Hospital St. Josef, University Regensburg, Landshuter
      Strasse 65, 93053 Regensburg, Germany
FAU - Mueller, S.
AU  - Mueller S
AD  - Department of Urology, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53105 
      Bonn, Germany
FAU - Eichhorn, F.
AU  - Eichhorn F
AD  - Outpatient Center, Rinckstrasse 7-9, 83435 Bad Reichenhall, Germany
FAU - Heinzer, H.
AU  - Heinzer H
AD  - Martini-Clinic at University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246
      Hamburg, Germany
FAU - Schmidt, K.
AU  - Schmidt K
AD  - Novartis Pharma GmbH, Roonstrasse 25, 90429 Nuernberg, Germany
FAU - Baier, M.
AU  - Baier M
AD  - Novartis Pharma GmbH, Roonstrasse 25, 90429 Nuernberg, Germany
FAU - Ruebel, A.
AU  - Ruebel A
AD  - Novartis Pharma GmbH, Roonstrasse 25, 90429 Nuernberg, Germany
FAU - Birkholz, K.
AU  - Birkholz K
AD  - Novartis Pharma GmbH, Roonstrasse 25, 90429 Nuernberg, Germany
FAU - Bakhshandeh-Bath, A.
AU  - Bakhshandeh-Bath A
AD  - Outpatient Center for Medical Oncology, Waitzstrasse 22, 22607 Hamburg, Germany
FAU - Andreesen, R.
AU  - Andreesen R
AD  - Department of Hematology and Oncology, University Hospital Regensburg,
      Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany
FAU - Herr, W.
AU  - Herr W
AD  - Department of Hematology and Oncology, University Hospital Regensburg,
      Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany
FAU - Reichle, A.
AU  - Reichle A
AD  - Department of Hematology and Oncology, University Hospital Regensburg,
      Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany
LA  - eng
PT  - Journal Article
DEP - 20141211
PHST- 2014/07/22 [received]
PHST- 2014/10/24 [accepted]
TA  - Cancer Microenviron
JT  - Cancer Microenvironment
AID - 161 [pii]
AID - 10.1007/s12307-014-0161-7 [doi]
SO  - Cancer Microenviron. 2014 Dec 11;8(1):33-41. doi:10.1007/s12307-014-0161-7.

PMC - PMC2486220
PMID- 20740935
VI  - 2
IP  - 101
DP  - 1854 Dec 08
TI  - PERISCOPIC REVIEW.
PG  - 1095-105
LA  - eng
PT  - Journal Article
PT  - Review
TA  - Assoc Med J
JT  - Association Medical Journal
SO  - Assoc Med J. 1854 Dec 08;2(101):1095-105.
